CYP2C - cytochrome P450-like Gene
Also Known as CYP2C3; CYPIIC3
Species: Oryctolagus cuniculus
Gene Type: protein coding
Gene ID: 100328933
CYP2C Products (1)
| mRNA | Protein | Name |
|---|---|---|
| NM_001171265.1 | NP_001164736.1 | cytochrome P450 2C3 precursor |
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
cytochrome P450 2C3 |
|
|
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
Bioactive Molecules
(20)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-17356 | Fenofibrate | 99.97% | Yes | |
| HY-103392 | Stiripentol | Inhibitor | 99.99% | Yes |
| HY-B0113 | Omeprazole | Inhibitor | 99.96% | Yes |
| HY-N6972 | Cepharanthine | 99.87% | Yes | |
| HY-B1218 | Sulfaphenazole | Inhibitor | 99.85% | Unkown |
| HY-B0258 | Gemfibrozil | 99.91% | Yes | |
| HY-17459 | Clopidogrel hydrogen sulfate | Inhibitor | 99.88% | Yes |
| HY-11103 | Sitaxsentan sodium | 98.83% | Unkown | |
| HY-100386 | Ticlopidine | Inhibitor | 99.74% | Unkown |
| HY-B0113A | Omeprazole sodium | Inhibitor | 99.10% | Yes |
| HY-N0482 | Phillyrin | 98.82% | Unkown | |
| HY-13463 | Avatrombopag | Agonist | 99.83% | Yes |
| HY-B0153A | Ticlopidine hydrochloride | Inhibitor | 99.99% | Unkown |
| HY-B1184 | Mephenytoin | 99.96% | Unkown | |
| HY-13463A | Avatrombopag maleate | 99.99% | Yes | |
| HY-B0113R | Omeprazole (Standard) | Inhibitor | 99.86% | Unkown |
| HY-13463B | Avatrombopag hydrochloride | Agonist | 97.05% | Yes |
| HY-76520 | Sitaxsentan | / | Unkown | |
| HY-109546 | Omeprazole magnesium | Inhibitor | / | Unkown |
| HY-17459R | Clopidogrel hydrogen sulfate (Standard) | Inhibitor | / | Unkown |
Clinical Phase
Bioactive Molecules
(11)
| Cat. No. | Product Name |
Effect
|
Purity |
Phase |
|---|---|---|---|---|
| HY-121872 | DP-b99 | Inhibitor | 95.0% | Phase 3 |
| HY-116780 | Prothipendyl | Substrate | / | Phase 3 |
| HY-N1201 | Apigenin | 99.22% | Phase 2 | |
| HY-50845 | Avagacestat | Inhibitor | 99.92% | Phase 2 |
| HY-19397 | BMS-223131 | / | Phase 2 | |
| HY-15565 | APD668 | 99.73% | Phase 1 | |
| HY-15566 | APD597 | Agonist | 99.97% | Phase 1 |
| HY-12946 | BI 653048 | Inhibitor | 99.84% | Phase 1 |
| HY-114415 | AWZ1066S | Inhibitor | 98.64% | Phase 1 |
| HY-12946A | BI 653048 phosphate | Inhibitor | / | Phase 1 |
| HY-19379 | E-2101 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
Bioactive Molecules
(160)
| Cat. No. | Product Name |
Effect
|
Purity |
Rare Diseases
|
|---|---|---|---|---|
| HY-129993 | Gemfibrozil 1-O-β-glucuronide | Inhibitor | 99.87% | Unkown |
| HY-N0319 | Salvianolic acid C | Inhibitor | 99.94% | Unkown |
| HY-B1184A | (S)-Mephenytoin | 99.94% | Unkown | |
| HY-N0904 | Ginsenoside C-K | Inhibitor | 99.93% | Unkown |
| HY-N0893 | Tetrahydrocurcumin | 98.96% | Unkown | |
| HY-15550 | 4'-Hydroxy diclofenac | 99.70% | Unkown | |
| HY-W008772 | 4-Hydroxymephenytoin | 99.77% | Unkown | |
| HY-N0043 | Ginsenoside Rd | Inhibitor | 99.88% | Unkown |
| HY-15550S | 4'-Hydroxy diclofenac-d4 | 98.92% | Unkown | |
| HY-W008364 | Olivetol | Inhibitor | 99.84% | Unkown |
| HY-W013268 | (S)-(+)-N-3-Benzylnirvanol | Inhibitor | 99.76% | Unkown |
| HY-N0762 | Isobavachin | 99.88% | Unkown | |
| HY-114759 | MS-PPOH | Inhibitor | 99.05% | Unkown |
| HY-W008772S | 4-Hydroxymephenytoin-d3 | 99.05% | Unkown | |
| HY-131968 | BMS-986202 | Inhibitor | 99.29% | Unkown |
| HY-100641 | 4-Hydroxytolbutamide | 99.69% | Unkown | |
| HY-137258 | (±)-N-3-Benzylnirvanol | Inhibitor | 99.86% | Unkown |
| HY-B1184AR | (S)-Mephenytoin (Standard) | 99.93% | Unkown | |
| HY-N1201R | Apigenin (Standard) | 98.82% | Unkown | |
| HY-170538 | SNT-5382 | Inhibitor | 99.96% | Unkown |
| HY-18063 | ML252 | Inhibitor | 99.9% | Unkown |
| HY-N0920 | Dihydrokavain | Inhibitor | 99.94% | Unkown |
| HY-N0688 | Linderane | Inhibitor | 98.61% | Unkown |
| HY-163996 | DD202-114 | 99.27% | Unkown | |
| HY-N1050 | Zederone | Inhibitor | 99.61% | Unkown |
| HY-100641S | 4-Hydroxytolbutamide-d9 | 99.29% | Unkown | |
| HY-125348 | 6α-Hydroxy paclitaxel | 99.93% | Unkown | |
| HY-135335 | 3'-Hydroxy Repaglinide | 98.20% | Unkown | |
| HY-129923 | (R)-Omeprazole sodium | Inhibitor | 98.07% | Unkown |
| HY-14362 | GSK-25 | Inhibitor | 98.33% | Unkown |
| HY-148822 | Nampt activator-2 | Activator | 98.79% | Unkown |
| HY-135334 | ACP-5862 | Inhibitor | 98.32% | Unkown |
| HY-128859 | EMT inhibitor-2 | Inhibitor | 98.83% | Unkown |
| HY-118283 | 5-Hydroxylansoprazole | Inhibitor | 99.75% | Unkown |
| HY-135331 | N-Desmethyl-Apalutamide | 99.08% | Unkown | |
| HY-116862 | Dibenzylfluorescein | 99.54% | Unkown | |
| HY-B0113S | Omeprazole-d3 | Inhibitor | 98.99% | Unkown |
| HY-147294 | Nivasorexant | 99.74% | Unkown | |
| HY-144652 | IDO1-IN-19 | Inhibitor | 98.82% | Unkown |
| HY-17356R | Fenofibrate (Standard) | 99.92% | Unkown | |
| HY-B0258R | Gemfibrozil (Standard) | 99.82% | Unkown | |
| HY-W157689 | IDE-IN-2 | Inhibitor | 98.04% | Unkown |
| HY-W587878 | Thujopsene | 86.31% | Unkown | |
| HY-116780A | Prothipendyl hydrochloride | Substrate | 99.94% | Unkown |
| HY-126857 | 5-Hydroxyomeprazole | ≥96.0% | Unkown | |
| HY-163438 | BKIDC-1553 | Inhibitor | 99.65% | Unkown |
| HY-17356S | Fenofibrate-d6 | 99.70% | Unkown | |
| HY-B0113S3 | Omeprazole-13C,d3 | Inhibitor | 98.00% | Unkown |
| HY-N1201S | Apigenin-d5 | 98.90% | Unkown | |
| HY-N5132 | (-)-Fenchone | 98.0% | Unkown | |
| HY-135335S | 3'-Hydroxy Repaglinide-d5 | 99.46% | Unkown | |
| HY-N8382 | Chalepensin | Inhibitor | 98.98% | Unkown |
| HY-W754151 | N-Desmethyl apalutamide-d4 | 99.63% | Unkown | |
| HY-124542 | 5-Hydroxydiclofenac | Inducer | 99.52% | Unkown |
| HY-15550S1 | 4'-Hydroxy diclofenac-13C6 | 99.21% | Unkown | |
| HY-B1351 | Bilberry Extract | / | Unkown | |
| HY-B0258S | Gemfibrozil-d6 | 98.71% | Unkown | |
| HY-131495 | (S)-6-O-Desmethylnaproxen | Inhibitor | 95.73% | Unkown |
| HY-135111 | 4-Desmethoxy Omeprazole | 98.99% | Unkown | |
| HY-135810 | Cletoquine | Inhibitor | / | Unkown |
| HY-135810A | Cletoquine oxalate | Inhibitor | 99.63% | Unkown |
| HY-141530 | Clopidogrel-β-D-glucuronide | Inhibitor | / | Unkown |
| HY-155732 | NPD-2975 | Inhibitor | 98.40% | Unkown |
| HY-186072 | NT-0527 | 99.80% | Unkown | |
| HY-B1184S1 | Mephenytoin-d5 | 98.72% | Unkown | |
| HY-U00048 | Bucolome | Inhibitor | 98.93% | Unkown |
| HY-Z2667 | (R)-Esomeprazole | Modulator | 96.41% | Unkown |
| HY-117160 | 4-trans-Hydroxy-glibenclamide | Inhibitor | 99.0% | Unkown |
| HY-125348S | 6α-Hydroxy Paclitaxel-d5 | 99.31% | Unkown | |
| HY-18063A | ML252 hydrochloride | Inhibitor | 98.5% | Unkown |
| HY-N6023 | Thermopsoside | 98.0% | Unkown | |
| HY-13024A | Rebastinib tosylate | / | Unkown | |
| HY-135390 | Hydroxy desmethyl Bosentan | / | Unkown | |
| HY-100386S | Ticlopidine-d4 | Inhibitor | / | Unkown |
| HY-135111S | 4-Desmethoxy Omeprazole-d3 | / | Unkown | |
| HY-100641S1 | 4-Hydroxytolbutamide-d9-1 | / | Unkown | |
| HY-103392S | Stiripentol-d9 | Inhibitor | / | Unkown |
| HY-105408A | Fandosentan potassium | / | Unkown | |
| HY-10575 | MK-5596 | / | Unkown | |
| HY-116601 | 6-Hydroxywarfarin | 99.87% | Unkown | |
| HY-116811 | AZ-11665362 | / | Unkown | |
| HY-119996 | AR-C141990 | Inhibitor | / | Unkown |
| HY-121698 | GW694481 | Inhibitor | / | Unkown |
| HY-122163 | MK-3901 | / | Unkown | |
| HY-13463BS | Avatrombopag-d8 hydrochloride | Agonist | / | Unkown |
| HY-135331S | N-Desmethyl-Apalutamide-15N,d4 | / | Unkown | |
| HY-135335S1 | 3'-Hydroxy Repaglinide-d7 | / | Unkown | |
| HY-135810S | Cletoquine-d4 | Inhibitor | / | Unkown |
| HY-135810S1 | Cletoquine-d4-1 | Inhibitor | / | Unkown |
| HY-137258A | (R)-N-3-Benzylnirvanol | Inhibitor | / | Unkown |
| HY-141547 | Nav1.7-IN-8 | Inhibitor | / | Unkown |
| HY-143906 | URAT1 inhibitor 2 | Inhibitor | / | Unkown |
| HY-145490 | trans-Hydroxy Glimepiride | / | Unkown | |
| HY-147807 | HIV-1 inhibitor-40 | Inhibitor | / | Unkown |
| HY-148597 | FGFR-IN-10 | Inhibitor | / | Unkown |
| HY-149866 | HIV-1 inhibitor-58 | Inhibitor | / | Unkown |
| HY-15042 | MK 0686 | 99.76% | Unkown | |
| HY-151251 | CYP2C9/CYP2C19-IN-1 | Inhibitor | / | Unkown |
| HY-151253 | CYP2C1/CYP2C19-IN-2 | Inhibitor | / | Unkown |
| HY-151254 | CYP2C19-IN-1 | Inhibitor | / | Unkown |
| HY-153970 | URAT1 inhibitor 7 | Inhibitor | 98.01% | Unkown |
| HY-155376 | mTOR inhibitor-14 | Inhibitor | / | Unkown |
| HY-156330 | HIV-IN-9 | Inhibitor | / | Unkown |
| HY-159143 | BChE-IN-33 | Inhibitor | / | Unkown |
| HY-163816 | Antiproliferative agent-53-d3 | Inhibitor | / | Unkown |
| HY-164031A | Cloperidone hydrochloride | Inhibitor | / | Unkown |
| HY-166530S | Ticlopidine-d6 hydrochloride | Inhibitor | / | Unkown |
| HY-167872 | Bifeprofen | Inhibitor | / | Unkown |
| HY-172393 | TCF4/β-catenin-IN-1 | / | Unkown | |
| HY-172897 | EGFR/DHFR-IN-2 | / | Unkown | |
| HY-173032 | VU6033685 | Agonist | / | Unkown |
| HY-17356G | Fenofibrate (GMP) | / | Unkown | |
| HY-17356S1 | Fenofibrate-d4 | / | Unkown | |
| HY-17459S | Clopidogrel-d3 hydrogen sulfate | / | Unkown | |
| HY-177070 | Angexostat | Inhibitor | / | Unkown |
| HY-178786 | RET-IN-31 | Inhibitor | / | Unkown |
| HY-179154 | α-Glucosidase-IN-101 | Inhibitor | / | Unkown |
| HY-181611 | Polθ-IN-10 | / | Unkown | |
| HY-182012 | DT-678 | / | Unkown | |
| HY-182602 | KOSN 1724 | Inhibitor | / | Unkown |
| HY-B0113S1 | Omeprazole-d3-1 | Inhibitor | 95.09% | Unkown |
| HY-B0153AS | Ticlopidine-d4 hydrochloride | Inhibitor | / | Unkown |
| HY-B1184S2 | Mephenytoin-d8 | / | Unkown | |
| HY-B1184S3 | Mephenytoin-13C,d3 | / | Unkown | |
| HY-B1218S | Sulfaphenazole-d4 | 99.66% | Unkown | |
| HY-N0043R | Ginsenoside Rd (Standard) | Inhibitor | / | Unkown |
| HY-N0893S | Tetrahydrocurcumin-d6 | / | Unkown | |
| HY-N0904R | Ginsenoside C-K (Standard) | Inhibitor | / | Unkown |
| HY-N1201S1 | Apigenin-13C | / | Unkown | |
| HY-N20617 | (2E,6E,10E)-12-Hydroxyfarnesol | / | Unkown | |
| HY-RS03457 | CYP2C18 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03458 | CYP2C19 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03459 | CYP2C8 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-RS03460 | CYP2C9 Human Pre-designed siRNA Set A | Pre-designed Set | / | Unkown |
| HY-W008364S1 | Olivetol-d9 | / | Unkown | |
| HY-W140208 | 3-Phenylthiophene | Inhibitor | / | Unkown |
| HY-W663179 | DNDI-VL-2098 | Inhibitor | / | Unkown |
| HY-W699866 | Gemfibrozil 1-O-β-glucuronide-d6 | / | Unkown | |
| HY-W707554 | Ticlopidine hydrochloride-d6 | / | Unkown | |
| HY-W777442 | Cletoquine-d4 Oxalate | Inhibitor | / | Unkown |
| HY-117925 | Personalised postprandial-targeting | Inhibitor | / | Unkown |
| HY-119311 | Ketopioglitazone | Agonist | / | Unkown |
| HY-134999 | 10-Hydroxywarfarin | Inhibitor | / | Unkown |
| HY-135334S | ACP-5862-d4 | Inhibitor | / | Unkown |
| HY-164031 | Cloperidone | Inhibitor | / | Unkown |
| HY-169119 | Antifungal agent 114 | Inhibitor | / | Unkown |
| HY-17356S2 | Fenofibrate-13C6 | / | Unkown | |
| HY-175169 | Urease-IN-21 | Inhibitor | / | Unkown |
| HY-175804 | M2 ion channel blocker-2 | Inhibitor | / | Unkown |
| HY-180227 | URAT1-IN-15 | Inhibitor | / | Unkown |
| HY-76520S | Sitaxsentan-13C6 | / | Unkown | |
| HY-B0113S2 | Omeprazole sulfone (methoxy-d3) | Inhibitor | 99.70% | Unkown |
| HY-B0113S4 | Omeprazole-d3 sodium | Inhibitor | / | Unkown |
| HY-B0113S5 | Omeprazole-d6 | Inhibitor | / | Unkown |
| HY-B0258S1 | Gemfibrozil-d6-1 | / | Unkown | |
| HY-B1184S | Mephenytoin-d3 | 99.52% | Unkown | |
| HY-N7482 | Pyranocoumarin | / | Unkown | |
| HY-W413619 | Cipargamin enantiomer | Inhibitor | / | Unkown |
| HY-W587570 | (S)-4-Hydroxymephenytoin | / | Unkown | |
| HY-W702646 | Hydroxymethyl tolperisone hydrochloride | Control | / | Unkown |